Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2024 Aug 14;57(3):798–805. doi: 10.1111/evj.14207

Correlation between kinematic parameters, ataxia and ground‐to‐lip distance in detomidine sedated horses

Jorge Izquierdo‐Moreno 1, Marta Illán de Paz 1, Gabriel Manso‐Díaz 1,✉, María Villalba‐Orero 1, Javier López‐Sanromán 1
PMCID: PMC11982421  PMID: 39140154

Abstract

Background

An accurate evaluation of the degree of sedation is mandatory to adjust the dosage of sedative drugs.

Objectives

To determine the correlation between head height above the ground and ataxia degree in horses sedated with detomidine and the correlation existing between accelerometric variables and both parameters.

Study design

In vivo experiment.

Methods

Twelve horses were given 0.01 mg/kg of detomidine hydrochloride iv. Measured accelerometric parameters, with one accelerometer positioned between both sacral tuberosities, included speed, stride frequency and length, regularity, dorsoventral, longitudinal, mediolateral and total accelerometric activities, relative force index and dorsoventral, longitudinal and mediolateral parts of the accelerometric activities. Head height above the ground (cm) and subjective ataxia degree were also measured. Baseline values (−15 min) and values measured 5 and 15 min after the injection and then every 15 min for a period of 2 h were obtained.

Results

There was a negative and strong correlation between head height above the ground and ataxia degree (Pearson r = −0.78, p < 0.001), particularly during the first 45 min. A significant correlation was found between head height above the ground and almost all accelerometric parameters. This correlation was very strong with stride frequency, regularity and dorsoventral and total accelerometric activities in both cases, but for ataxia, also with total accelerometric activity.

Main limitations

Experimental conditions may not represent real clinical situations.

Conclusions

Stride frequency and regularity are the most reliable parameters to determine degree of sedation and are related to the sedation produced. Ataxia should not be considered a separate property of sedation and does not need to be assessed separately to the depth of sedation.

Keywords: accelerometry, anaesthesia, ataxia, gait analysis, horse, sedation

1. INTRODUCTION

Evaluating the degree of sedation is used to adjust the dose of the different sedatives. One of the most frequently used objective methods is determining the head height above the ground (HHAG) expressed in cm 1 or as a percentage compared with the baseline. 2 This parameter is correlated to the degree of sedation 3 and is related to the myorelaxation caused by the sedative drugs. Subjective and objective simple descriptive scales (SDS), numerical rating scales (NRS), visual analogue scales (VAS) and multifactorial sedation scales have also been used to assess depth, quality and postural instability/ataxia and the latter is considered to be partly related to the depth of sedation. 4

For ataxia, several subjective scales have been described. 5 , 6 , 7 Instability or ataxia can be considered a separate property of sedation, considering the degree of ataxia separately from the depth of sedation when developing a sedation scoring system to adjust the administration rate of sedatives in a clinical setting. 4 Conversely, some studies include ataxia or instability as a parameter to quantify the depth of sedation 8 , 9 by incorporating the degree of instability as a clinical observation to determine sedation in an SDS, 10 the degree of ataxia in a NRS 11 or using VAS scores to assess ataxia as a specific aspect of sedation. 12 , 13

In the last decade, accelerometry has been used to objectively assess alterations in gait produced by different sedative and analgesic drugs. 14 , 15 , 16 Accelerometry is a practical, quick, accurate, easy‐to‐use, portable and low‐cost method to monitor the gait pattern in horses. 17 Also, regularity, a specific accelerometric parameter, could be useful to grade certain conditions and rate the efficiency of treatments, such as in horses with neurological conditions characterised by ataxia. 17 , 18 Thus, accelerometry was able to detect dose‐dependent effects in kinematic, coordination and energetic parameters after the administration of various α2 adrenoceptor agonist drugs in horses. 14

The objective of this study was to determine the correlation between HHAG and ataxia degree in horses sedated with detomidine, a commonly used α2 adrenoceptor agonist, and to determine the correlation existing between accelerometric variables and both HHAG and ataxia degree. Because both the degree of sedation and ataxia are related to the myorelaxation produced after the administration of an α2 adrenoceptor agonist drug, we hypothesised that there would be a strong correlation between the degree of sedation and the ataxia occurring after detomidine administration. Accelerometry can potentially be used to validate other ataxia subjective scales. Thus, our secondary goal was to correlate the degree of sedation and ataxia, assuming that accelerometry could be an important objective method to be used while determining the depth of sedation in horses.

2. MATERIALS AND METHODS

2.1. Animals

Twelve adult horses, part of the livestock collection of the Department of Animal Medicine and Surgery of the Universidad Complutense de Madrid, with a mean body mass ± SD of 468.5 ± 33.6 kg (range: 403–535 kg) and a mean age of 13.6 ± 7.4 years (range: 2–27 years) were used. Using correlation criteria previously described, 19 and assuming the presence of several parameters with a very strong correlation between HHAG and ataxia (r > 0.7), we estimated a sample size of 12 horses; accepting an alpha risk of 0.05 and a beta risk of 0.2 in a two‐sided test, presupposing a correlation coefficient of 0.8. It has been anticipated that erroneous data at several time points for HHGA might be 15%. A routine physical examination was performed on all horses to ensure they were healthy and to exclude obvious orthopaedic problems. The horses were accustomed to the experimental conditions and all tests and measurements were undertaken in a quiet and comfortable environment.

2.2. Treatment

The present is a retrospective study analysing data acquired from previous prospective, blind, randomised and crossover studies in which detomidine was compared with other treatments. In all cases, on the day of the study and after obtaining the baseline accelerometric measurements, an intravenous 16G catheter (Surflo® I.V. Catheter) was placed in the left jugular vein, and the horse was injected with a total of 0.01 mg/kg of detomidine hydrochloride (Detogesic®) diluted in saline solution to a total volume of 10 mL. Immediately after the drug administration the catheter was removed.

2.3. Experimental protocol

Data were acquired using the Equimetrix portable gait analyser (Equimetrix®) including an acceleration sensor, a data logger, and a scientific software program (Matlab 5, The MathWorks) for processing the acceleration signals. The acceleration sensor used is a tri‐axial accelerometric device and consists of three orthogonal accelerometers. The device was positioned between both sacral tuberosities, enabling a continuous measure of accelerations along the three axial planes (dorsoventral, longitudinal and lateral axes) of the horse while the animals were walking with a collection sampling rate of 100 Hz (measuring range ±10 g). Positive values were obtained when accelerations were in dorsal, cranial and left directions. The data logger was carried in a pocket fixed on an elastic girth fastened onto the thorax and transferred data to a computer after the tests were finished.

The accelerometric device was attached to the skin over the midline of the sacrum region. Fifteen minutes before the drug injection, the horse was walked three times over a 50‐m‐long concrete track covered by a 2‐cm‐thick rubber mat at its own comfortable speed to obtain baseline accelerometric parameter values. After injecting the treatment, the accelerometric recordings were then repeated, 5 and 15 min after the injection and then every 15 min for a total period of 2 h. The horses were walked once 5 min after injection and twice in the remaining recordings (at 15, 30, 45, 60, 75, 105 and 120 min).

Validation and reproducibility of the accelerometric measurements taken with Equimetrix® have been described 20 , 21 , 22 and the following kinematic, coordination and energetic parameters studied have also been well described. 16 , 23 The stride kinematic parameters studied were speed (SP; m/s), stride frequency (SF; cycle/s or Hz) and stride length (SL; m). The coordination parameter included in the current study was regularity (REG; dimensionless), which measured the acceleration pattern similarity of successive strides over time and was calculated by adding two coefficients of correlation obtained by calculating the autocorrelation function on the dorsoventral acceleration signal. The energetic parameters included the dorsoventral accelerometric activity or dorsoventral power (DVAA; W/kg or g2/Hz), longitudinal accelerometric activity or craniocaudal accelerometric activity or propulsion power (LAA; W/kg or g2/Hz), mediolateral accelerometric activity or side‐to‐side accelerometric activity or mediolateral power (MLAA; W/kg or g2/Hz) and the total accelerometric activity or total power (TAA; W/kg or g2/Hz) defined as the sum of the three accelerometric activities calculated on each axis. The relative force index or force of acceleration (RFI; N/kg) was also calculated by dividing the TAA by SP and was used to avoid a potential bias in the calculation of the TAA due to different speeds. 23 Finally, the redistribution of the dorsoventral, longitudinal and mediolateral parts of the accelerometric activities (%DVAA, %LAA and %MLAA; %) were also calculated by dividing the different accelerometric activity parts by the TAA. A description of the studied parameters is summarised in Table S1.

Using the software, each accelerometric parameter was calculated at each walking trial, at least five times at different time instants of stabilised walking by eliminating the first 5 s and the last seconds due to the non‐stable strides. The final value for each parameter at each time point was calculated as the mean of all the measurements: three trials for the baseline value (−15 min), once 5 min after the injection and twice in the following time points (at 15, 30, 45, 60, 75, 90, 105 and 120 min after the drug administration).

Baseline values of HHAG (cm) and ataxia were measured 15 min before the drug injection. Afterwards, HHAG to evaluate the sedation depth of the animals was determined before the walking test performed at each time point. HHAG was determined using a modified technique to that described by Ringer et al., 24 employing a stiff tape to measure the distance in centimetres from the lowest point of the lip to the ground. Ataxia was also graded while walking during the first walking trial of each time point according to a 5‐point ataxia scale originally described by Mayhew et al. 5 and modified by Reed et al. 6 for ataxic gait analysis. Grades were rated as follows: Grade 0, no gait deficits at the walk. In Grade 1, no gait deficits were identified at the walk and deficits were only identified during further testing. Grade 2, deficits noted at the walk. Grade 3, marked deficits noted at the walk. Grade 4, severe deficits noted at the walk and may fall or nearly fall. No recumbent horses (Grade 5) were observed in this study.

2.4. Data analysis

All the individual data were expressed and analysed in percentages (%) compared with the baseline values for each horse, treatment and time to standardise the data and prevent possible variations due to physical differences in the horses used. The baseline for each horse and treatment corresponded to 100% and the successive obtained values corresponded to a percentage compared with the baseline. Data were collected and processed in the database created via MS Excel for Mac v.16.62 and SPSS v.21.0 for Windows. Graphics were performed using GraphPad Prism 9.4.1.

A Kolmogorov–Smirnov test was used to confirm data normality distribution. To assess the relationships between the measured variables, pairwise correlations were calculated (Pearson's correlation coefficient, r). Correlations between the variables were interpreted as follows: r < 0.19—no correlation, r > 0.19 and <0.29—weak correlation, r > 0.3 and <0.49—moderate correlation, r > 0.5 and <0.69—strong correlation, r > 0.7—very strong correlation. 19 In addition, the percentage of change induced by detomidine administration in ataxia and HHAG was represented among time, and the area under the curve (AUC) was calculated by the trapezoidal method. Differences were evaluated using a Student t‐test. As the representation of changes in both parameters revealed a slight discrepancy in the last time period studied, the correlation of these two parameters was also assessed for the first and second studied periods (0–45 and 60–120 min, respectively). Data are presented as mean ± SD. The significance level was set to p < 0.05.

3. RESULTS

All the horses involved in the present project completed the study and all the data were included in the statistical analysis. There was a negative, statistically significant and very strong correlation (Pearson r = −0.78, p < 0.001) between HHAG and ataxia degree (Figure 1A). Moreover, the change in these two parameters over time was very similar during the time studied (AUC ataxia: 5905 ± 379.5 vs. AUC HHAG: 5009 ± 379.5; p = ns; Figure 1B,C). As shown in Figure 1D, when analysing correlations among time, a stronger correlation was observed during the first 45 min (r = −0.88, p < 0.001) and a lesser correlation during the second hour of the experimental measurements (r = −0.59, p < 0.001).

FIGURE 1.

FIGURE 1

(A) Correlation between the degree of ataxia and the head height above the ground (HHAG), in horses sedated with detomidine (0.01 mg/kg bwt). (B, C) Percent of changes in the degree of ataxia and HHAG over time (B) and its corresponding area under the curve (AUC; C) (Student t‐test; ns = nonsignificant). (D) Correlation between the degree of ataxia and HHAG, over the first 45 and 60 min after detomidine administration. For correlations (Pearson correlation coefficient), the dots represent the values obtained for each of the variables, while the line represents the best fit for the correlation.

There was a statistically significant correlation between HHAG and all the accelerometric parameters but %LAA. Very strong positive correlations were observed between HHAG and DVAA (Pearson r = 0.78, p < 0.001), SF (Pearson r = 0.75, p < 0.001), REG (Pearson r = 0.75, p < 0.001) and TAA (Pearson r = 0.76, p < 0.005) (Figure 2). Strong positive correlations were shown between HHAG and LAA values (Pearson r = 0.69, p < 0.001), RFI (Pearson r = 0.65, p < 0.001), SP (Pearson r = 0.63, p < 0.001) and %DVAA values (Pearson r = 0.58, p < 0.001). A moderate positive correlation was observed between HHAG and MLAA (Pearson r = 0.47, p < 0.001). A moderate negative correlation was shown between %MLAA and HHAG (Pearson r = −0.38, p = 0.001). Finally, a weak positive correlation appeared between SL and HHAG (Pearson r = 0.24, p = 0.01).

FIGURE 2.

FIGURE 2

Correlation between the head height above the ground (HHAG) and (A) stride frequency (SF), (B) regularity (REG), (C) dorsoventral accelerometric activity (DVAA) and (D) total accelerometric activity (TAA)in horses sedated with detomidine (0.01 mg/kg bwt; Pearson correlation coefficient). The dots represent the values obtained for each of the variables, while the line represents the best fit for the correlation.

There was a statistically significant correlation between ataxia degree and all the accelerometric parameters but %LAA. A very strong negative correlation was observed between ataxia degree and DVAA (Pearson r = −0.76, p < 0.001), SF (Pearson r = −0.72, p < 0.001), REG (Pearson r = −0.70, p < 0.001), TAA (Pearson r = −0.73, p < 0.001) and LAA (Pearson r = −0.76, p < 0.001) (Figure 3). Strong negative correlations were shown between ataxia degree and SP (Pearson r = −0.65, p < 0.001) and RFI (Pearson r = −0.59, p < 0.001). Finally, a moderate positive correlation was shown between %MLAA and ataxia degree (Pearson r = 0.37, p = 0.001) and between %DVAA and ataxia values (Pearson r = 0.58, p < 0.001) and a moderate negative correlation between SL and ataxia degree (Pearson r = −0.32, p = 0.008).

FIGURE 3.

FIGURE 3

Correlation between the degree of ataxia and (A) stride frequency (SF), (B) regularity (REG), (C) dorsoventral accelerometric activity (DVAA), (D) total accelerometric activity (TAA) and (E) longitudinal accelerometric activity (LAA), over the time, in horses sedated with detomidine (0.01 mg/kg bwt). The dots represent the values obtained for each of the variables, while the line represents the best fit for the correlation.

Values of Pearson r correlation analysis after comparison of HHAG and ataxia with stride kinematics, coordination and energetic parameters are summarised in Table 1.

TABLE 1.

Pearson correlation coefficient (r) and level of significance (p) between the accelerometric parameters of interest and the head height above the ground and ataxia degree.

Accelerometric parameter Ataxia degree HHAG
Correlation coefficient (r) p Value Correlation coefficient (r) p Value
SP −0.65 <0.001 0.63 <0.001
SF −0.72 <0.001 0.75 <0.001
SL −0.32 0.008 0.24 0.01
REG −0.70 <0.001 0.75 <0.001
DVAA −0.76 <0.001 0.78 <0.001
LAA −0.76 <0.001 0.69 <0.001
MLAA −0.44 <0.001 0.47 <0.001
TAA −0.73 <0.001 0.76 <0.005
RFI −0.59 <0.001 0.65 <0.001
%DVAA −0.58 <0.001 0.58 <0.001
%LAA 0.14 0.16 −0.06 0.54
%MLAA 0.37 0.001 −0.38 <0.001

Note: Very strong correlation coefficients obtained are shown in bold.

Abbreviations: %DVAA, dorsoventral component of the accelerometric activity; %LAA, longitudinal component of the accelerometric activity; %MLAA, mediolateral component of accelerometric activity; DVAA, dorsoventral accelerometric activity; LAA, longitudinal accelerometric activity; MLAA, mediolateral accelerometric activity; REG, regularity; RFI, relative force index; SF, stride frequency; SL, stride length; SP, speed; TAA, total accelerometric activity.

4. DISCUSSION

Our results show that with detomidine, at a dose of 0.01 mg/kg, the behaviour of the values obtained for HHAG and for the degree of ataxia were very similar, with a very strong correlation between them (Pearson r = −0.78). This is the first time that a correlation has been determined between two separate variables (objective and subjective) that are, however, frequently used to assess the depth of sedation of certain drugs. HHAG is a consecrated objective parameter, easy to measure and reproducible, frequently used in experimental studies but with some restrictions in clinical studies, especially when the head needs to be supported while performing certain procedures such as dental or sinus surgery. 4 The sedative effects of alfa‐2 agonists are often associated with ataxia 25 and the determination of the degree of ataxia or instability has also been frequently incorporated in different experimental or clinical studies to determine depth of sedation. Ataxia occurs mainly as a consequence of the myorelaxation produced after the administration of the α2 agonist drugs 26 and the same has been described for the decrease in the height of the head. 16 These findings indicate that both parameters could be used to determine the degree of sedation because the values are strongly correlated and that the use of an objective method such as the ground‐to‐lip distance could be potentially enough to evaluate the depth of sedation, at least with this drug and at this dose, because the depth and duration of the sedative effects are both dose and individual horse related. 25 Interestingly, the change in both parameters, HHAG and ataxia, among time was very similar during the 120‐min period studied. When the correlation was studied over time, a stronger correlation (r = 0.88, p < 0.001) was observed during the first 45 min after the administration of detomidine, while during the second hour, the correlation was less strong. This result is especially important and can be transferred to the clinical setting when a bolus of detomidine is administered. After a bolus sedation, the effects desired need to be immediate and time‐limited and we observed a very strong correlation, specifically, during these first minutes after administration.

When comparing both the HHAG and the ataxia degree values with the accelerometric parameters, a very strong correlation was also observed for different parameters. SP is a critical parameter that influences the kinematics and kinetics of the gait 27 and is the result of the product of SL and SF. Using an instrumented treadmill, both SL and SF changed in a linear fashion with SP 27 while in an overground condition, the primary contributor to SP changes was the SL. 28 SL is not altered after the administration of α2 agonist drugs 14 while invariably SF decreases after the administration of these drugs being the major contributor to the decrease in SP observed in the present study occurring because of the inhibition of the locomotor activity described after the administration of these drugs. 17 , 29 In the present study, SF showed a strong correlation with both HHAG (Pearson r = 0.75) and ataxia values (Pearson r = −0.72), while SP showed only a strong correlation (Pearson r = 0.63 for HHAG and Pearson r = −0.65 for ataxia values). This result indicates that the reduction in the locomotor activity causing the decrease in the SF is a very important secondary effect closely correlated to the degree of sedation is also dose related.

Regularity is an accelerometry‐specific variable that measures the stride‐to‐stride variability during locomotion 16 and has been mentioned as a potentially useful variable when assessing ataxia 17 and in fact, in the present study, a strong correlation was observed when compared with both parameters (Pearson r = 0.75 for HHAG and Pearson r = −0.7 for ataxia values). This was a predictable result but, interestingly, not more different than other stride kinematic parameters.

Accelerometric activity, specifically, the DVAA (Pearson r = 0.78 for HHAG and Pearson r = −0.76) and the LAA (Pearson r = 0.76 for HHAG and Pearson r = −0.76 for ataxia values) showed very strong correlations in both cases. Also, a very strong correlation was observed with TAA (Pearson r = 0.73) in the case of ataxia values. These accelerometric activity variables, especially DVAA, showed the highest correlation values of all the parameters studied. The reduction in the accelerometric activity values is probably the result of the myorelaxation previously described, but this activity is also closely related to SP. 22 , 30 That is the reason why the RFI is calculated by dividing TAA values by the SP. This parameter is determined as a mean to avoid possible bias due to changes in SP 23 and the results showed only strong correlations for RFI values (Pearson r = 0.65 for HHAG and Pearson r = −0.59). These results suggest that the high correlations observed with the DVAA, LAA and TAA are influenced by the reduction in SP because of the α2 agonist drug administration effect and that the accelerometric activity variables are not the best indicators of the sedation depth and ataxia degree in detomidine sedated horses being SF and REG the most reliable to evaluate the degree of sedation after the administration of detomidine in horses.

The present study has some limitations. Some parameters might by influenced by external stimuli, for instance, movement, and it may be argued that a limitation in the depth of sedation could be produced by this movement. Although a 15 min acclimation period for the horse was carried out between measurements, this experimental scenario does not mimic a typical clinical situation in which the clinicians sedate and maintain sedation of a horse in a stock or at least without moving it. On the other hand, it is frequent to disturb the horse with other procedures (injections, intubations, explorations…), which can also disturb and limit the depth of sedation. We think that these 15‐min acclimation periods between measurements were sufficient to have the horse undisturbed for the following measurement. Also, the docile temperament and previous adaptation of the animals to the experimental conditions could potentially not thoroughly mimic a real clinical situation.

5. CONCLUSIONS

Accelerometry is a very useful and sensitive objective method to assess the degree of sedation produced after the administration of α2 agonist drugs in horses, specifically detomidine and at a dose of 0.01 mg/kg. In conclusion, if what we try with this study is to identify the most reliable accelerometric variable with which to assess the sedation after the administration of detomidine in horses, the response should be SF and REG. Both seem to be the most reliable and strongly correlated variables being the values obtained for these variables strictly due to the sedation produced after the drug administration. Ataxia should not be considered a separate property of sedation and does not need to be assessed separately to the depth of sedation because both variables are strongly correlated, especially during the first hour after the drug administration, and both are the result of the same myorelaxation effect.

FUNDING INFORMATION

Not applicable.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

Jorge Izquierdo‐Moreno: Methodology; investigation; writing – review and editing. Marta Illán de Paz: Methodology; investigation. Gabriel Manso‐Díaz: Writing – review and editing; supervision. María Villalba‐Orero: Formal analysis; supervision; writing – review and editing; data curation. Javier López‐Sanromán: Data curation; conceptualization; investigation; writing – original draft; writing – review and editing; supervision; project administration.

DATA INTEGRITY STATEMENT

Jorge Izquierdo‐Moreno had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

ETHICAL ANIMAL RESEARCH

The study was approved by the Complutense Veterinary Teaching Hospital Animal Care and Use Committee under protocol 04/2022.

INFORMED CONSENT

Not applicable.

PEER REVIEW

The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/evj.14207.

Supporting information

Table S1. Description of the studied parameters, including units, definitions, technical characteristics and calculation methods (adapted from Frigerio et al. 16 ).

EVJ-57-798-s001.pdf (189.3KB, pdf)

ACKNOWLEDGEMENTS

We thank the graduate and undergraduate students who collaborated on this study.

Izquierdo‐Moreno J, de Paz MI, Manso‐Díaz G, Villalba‐Orero M, López‐Sanromán J. Correlation between kinematic parameters, ataxia and ground‐to‐lip distance in detomidine sedated horses. Equine Vet J. 2025;57(3):798–805. 10.1111/evj.14207

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are openly available in DOCTA Complutense at docta.ucm.es/workflowitems/5903/view, reference number 10.5281/zenodo.10497084.

REFERENCES

  • 1. Clarke KW, England GCW, Goossens L. Sedative and cardiovascular effects of romifidine, alone and in combination with butorphanol, in the horse. J Vet Anaesth. 1991;18(1):25–29. 10.1111/j.1467-2995.1991.tb00008.x [DOI] [Google Scholar]
  • 2. England GC, Clarke KW, Goossens L. A comparison of the sedative effects of three α2‐adrenoceptor agonists (romifidine, detomidine and xilazyne) in the horse. J Vet Pharmacol Ther. 1992;15(2):194–201. 10.1111/j.1365-2885.1992.tb01007.x [DOI] [PubMed] [Google Scholar]
  • 3. Figueiredo JP, Muir WW, Smith J, Wolfrom GW. Sedative and analgesic effects of romifidine in horses. Int J Appl Res Vet Med. 2005;3(3):249–258. [Google Scholar]
  • 4. Schauvliege S, Cuypers C, Michielsen A, Gasthuys F, Gozalo‐Marcillla M. How to score sedation and adjust the administration rate of sedatives in horses: a literature review and introduction of the Ghent sedation algorithm. Vet Anaesth Analg. 2019;46(1):4–13. 10.1016/j.vaa.2018.08.005 [DOI] [PubMed] [Google Scholar]
  • 5. Mayhew IG, deLahunta A, Whitlock RH, Krook L, Tasker JB. Spinal cord disease in the horse. Cornell Vet. 1978;68(suppl 6):1–207. [PubMed] [Google Scholar]
  • 6. Reed SM. Neurologic exam. J Equine Vet. 2003;23(11):484–492. 10.1016/j.jevs.2003.10.013 [DOI] [Google Scholar]
  • 7. Lunn DP, Mayhew IG. The neurological evaluation of horses. Equine Vet Educ. 1989;1(2):94–101. 10.1111/j.2042-3292.1989.tb01355.x [DOI] [Google Scholar]
  • 8. Rohrbach H, Korpivaara T, Schatzmann U, Spadavecchia C. Comparison of the effects of the alpha‐2 agonists detomidine, romifidine and xylazine on nociceptive withdrawal reflex and temporal summation in horses. Vet Anaesth Analg. 2009;36(4):384–395. 10.1111/j.1467-2995.2009.00466.x [DOI] [PubMed] [Google Scholar]
  • 9. de Vries A, Pakkanen SA, Raekallio MR, Ekiri A, Scheinin M, Taylor PM, et al. Clinical effects and pharmacokinetic variables of romifidine and the peripheral α‐2 adrenoceptor antagonist MK‐467 in horses. Vet Anaesth Analg. 2016;43(6):599–610. 10.1111/vaa.12354 [DOI] [PubMed] [Google Scholar]
  • 10. Hamm D, Jöchle W. Sedation and analgesia with dormosedan® (Detomidine hydrochloride) or acepromazine for suturing of the vulvar lips in mares (Caslick's surgery). J Equine Vet. 1991;11(2):86–88. 10.1016/S0737-0806(07)80136-5 [DOI] [Google Scholar]
  • 11. Bryant CE, England GCW, Clarke KW. Comparison of the sedative effects of medetomidine and xylazine in horses. J Vet Anaesth. 1991;18(S1):55–57. 10.1111/j.1467-2995.1991.tb00511.x [DOI] [PubMed] [Google Scholar]
  • 12. Freeman SL, England GCW. Investigation of romifidine and detomidine for the clinical sedation of horses. Vet Rec. 2000;147(18):507–511. 10.1136/vr.147.18.507 [DOI] [PubMed] [Google Scholar]
  • 13. Ringer SK, Portier K, Torgerson PR, Castagno R, Bettshart‐Wolfensberger R. The effects of a loading dose followed by constant rate infusion of xylazine compared with romifidine on sedation, ataxia and response to stimuli in horses. Vet Anaesth Analg. 2013;40(2):157–165. 10.1111/j.1467-2995.2012.00784.x [DOI] [PubMed] [Google Scholar]
  • 14. López‐Sanromán FJ, Holmbak‐Petersen R, Varela M, del Alamo AM, Santiago I. Accelerometric comparison of the locomotor pattern of horses sedated with xylazine hydrochloride, detomidine hydrochloride or romifidine hydrochloride. Am J Vet Res. 2013;74(6):828–834. 10.2460/ajvr.74.6.828 [DOI] [PubMed] [Google Scholar]
  • 15. López‐Sanromán FJ, Gomez Cisneros D, Verla del Arco M, Santiago Llorente I, Santos González M. The use of low doses of acepromazine as an aid for lameness diagnosis in horses: an accelerometric evaluation. Vet Comp Orthop Traumatol. 2015;28(5):312–317. 10.3415/VCOT-14-11-0177 [DOI] [PubMed] [Google Scholar]
  • 16. Frigerio MA, Gómez Cisneros D, Santiago Llorente I, Manso‐Díaz G, López‐Sanromán J. A kinematic comparison of the locomotor pattern of horses sedated with detomidine alone and in combination with low doses of butorphanol. Equine Vet J. 2019;51(6):825–830. 10.1111/evj.13098 [DOI] [PubMed] [Google Scholar]
  • 17. López‐Sanromán FJ, Holmbak‐Petersen R, Santiago I, Gómez de Segura IA, Barrey E. Gait analysis using 3D accelerometry in horses sedated with xylazine. Vet J. 2012;193(1):212–216. 10.1016/j.tvjl.2011.10.012 [DOI] [PubMed] [Google Scholar]
  • 18. Auvinet B, Alix AS, Chaleil D, Brun M, Barrey E. Gait regularity: measurement and significance. Gait Posture. 2005;21(1):s143. 10.1016/S0966-6362(05)80469-2 [DOI] [Google Scholar]
  • 19. Hagen J, Kojah K, Geiger M. Correlations between the equine metacarpophalangeal joint angulation and toe conformation in statics. Open Vet J. 2018;8(1):96–103. 10.4314/ovj.v8i1.15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Barrey E, Auvinet B, Couroucé A. Gait evaluation of race trotters using an accelerometric device in equine gait analysis. Equine Vet J. 1995;27(s18):156–160. 10.1111/j.2042-3306.1995.tb04910.x 7541746 [DOI] [Google Scholar]
  • 21. Leleu C, Bariller F, Cotrel C, Barrey E. Reproducibility of a locomotor test for trotter horses. Vet J. 2004;168(2):160–166. 10.1016/S1090-0233(03)00109-6 [DOI] [PubMed] [Google Scholar]
  • 22. Barthélémy I, Barrey E, Thibaud JL, Uriarte A, Voit T, Blot S, et al. Gait analysis using accelerometry in dystrophin‐deficient dogs. Neuromuscul Disord. 2009;19(11):788–796. 10.1016/j.nmd.2009.07.014 [DOI] [PubMed] [Google Scholar]
  • 23. Barthélémy I, Barrey E, Aguilar P, Uriarte A, Le Chevoir M, Thibaud JL. Longitudinal ambulatory measurements of gait abnormality in dystrophin‐deficient dogs. BMC Musculoskelet Disord. 2011;12:75. 10.1186/1471-2474-12-75 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Ringer SK, Portier K, Fourel I, Bettshart‐Wolfensberger R. Development of a xylazine constant rate infusion with or without butorphanol for standing sedation of horses. Vet Anaesth Analg. 2012;39(1):1–11. 10.1111/j.1467-2995.2011.00653.x [DOI] [PubMed] [Google Scholar]
  • 25. Zeiler GE. A review of clinical approaches to antagonism of alpha2‐adrenoreceptor agonists in the horse. Equine Vet Educ. 2015;27(1):48–54. 10.1111/eve.12249 [DOI] [Google Scholar]
  • 26. Nannarone S, Gialletti R, Veschini I, Bufalari A, Moriconi F. The use of alpha‐2 agonists in the equine practice: comparison between three molecules. Vet Res Commun. 2007;31(S1):309–312. 10.1007/s11259-007-0103-7 [DOI] [PubMed] [Google Scholar]
  • 27. Weishaupt MA, Hogg HP, Auer JA, Wiestner T. Velocity‐dependent changes of time, force and spatial parameters in Warmblood horses walking and trotting on a treadmill. Equine Vet J. 2010;42(s38):530–537. 10.1111/j.2042-3306.2010.00190.x [DOI] [PubMed] [Google Scholar]
  • 28. Clayton HM. Comparison of the stride kinematics of the collected, medium and extended walks in horses. Am J Vet Res. 1995;56(7):849–852. [PubMed] [Google Scholar]
  • 29. Lähdesmäki J, Sallinen J, MacDonald E, Sirviö J, Scheinin M. α2‐Adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the α2A‐adrenoceptor subtype. Neuropharmacology. 2003;44(7):882–892. 10.1016/s0028-3908(03)00080-7 [DOI] [PubMed] [Google Scholar]
  • 30. Barrey E, Evans SE, Evans DL, Curtis RA, Quinton R, Rose RJ. Locomotion evaluation for racing in Thoroughbreds. Equine Vet J. 2001;33(S33):99–103. 10.1111/j.2042-3306.2001.tb05369.x [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Table S1. Description of the studied parameters, including units, definitions, technical characteristics and calculation methods (adapted from Frigerio et al. 16 ).

EVJ-57-798-s001.pdf (189.3KB, pdf)

Data Availability Statement

The data that support the findings of this study are openly available in DOCTA Complutense at docta.ucm.es/workflowitems/5903/view, reference number 10.5281/zenodo.10497084.


Articles from Equine Veterinary Journal are provided here courtesy of Wiley

RESOURCES